Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal cancer

Demir, Ahmet Suat; Erdenen, Füsun; Muderrisoglu, Cüneyt; Toros, Ahmet Burak; Bektaş, Hasan; Gelışgen, Remise; Tabak, Ömür; Altunoğlu, Esma; Uzun, Hafize; Huq, Gülben Erdem; Aral, Hale

doi:10.4318/tjg.2013.0607

Cited by 14 publications

(9 citation statements)

References 23 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PKM2 is a cytosolic enzyme involved in energy metabolism that is expressed by both normal proliferating cells and cancer cells. Elevated expression of the tumour-specific dimeric form of this protein has been reported in CRC and other gastrointestinal cancers [ 39 – 41 ] and numerous studies have evaluated its usefulness as a faecal or blood-based marker for CRC screening and/or diagnosis [ 40 , 42 – 46 ]. The primary disadvantage concerning its utility as a stand-alone diagnostic marker has been its poor specificity for CRC.…”

Section: Discussionmentioning

confidence: 99%

Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer

et al. 2015

View full text Add to dashboard Cite

BackgroundThe majority of colorectal cancer (CRC) cases are preventable by early detection and removal of precancerous polyps. Even though CRC is the second most common internal cancer in Australia, only 30 per cent of the population considered to have risk factors participate in stool-based test screening programs. Evidence indicates a robust, blood-based, diagnostic assay would increase screening compliance. A number of potential diagnostic blood-based protein biomarkers for CRC have been reported, but all lack sensitivity or specificity for use as a stand-alone diagnostic. The aim of this study was to identify and validate a panel of protein-based biomarkers in independent cohorts that could be translated to a reliable, non-invasive blood-based screening test.Principal FindingsIn two independent cohorts (n = 145 and n = 197), we evaluated seven single biomarkers in serum of CRC patients and age/gender matched controls that showed a significant difference between controls and CRC, but individually lack the sensitivity for diagnostic application. Using logistic regression strategies, we identified a panel of three biomarkers that discriminated between controls and CRC with 73% sensitivity at 95% specificity, when applied to either of the two cohorts. This panel comprised of Insulin like growth factor binding protein 2 (IGFBP2), Dickkopf-3 (DKK3), and Pyruvate kinase M2(PKM2).ConclusionsDue to the heterogeneous nature of CRC, a single biomarker is unlikely to have sufficient sensitivity or specificity for use as a stand-alone diagnostic screening test and a panel of markers may be more effective. We have identified a 3 biomarker panel that has higher sensitivity and specificity for early stage (Stage I and -II) disease than the faecal occult blood test, raising the possibility for its use as a non-invasive blood diagnostic or screening test.

show abstract

Section: Discussionmentioning

confidence: 99%

Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…PKM2 is an isoform of cytosolic enzyme pyruvate kinase (PK) involved in energy metabolism and is present in normal and cancer cells. Overexpression of PKM2 has been reported in CRC, gastric cancer and colon adenomas [ 190 , 191 , 192 , 193 ].…”

Section: Blood Biomarkersmentioning

confidence: 99%

Novel Diagnostic Biomarkers in Colorectal Cancer

Zygulska¹,

Pierzchalski

2022

IJMS

114

View full text Add to dashboard Cite

Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease associated with a number of genetic or somatic mutations. Diagnostic markers are used for risk stratification and early detection, which might prolong overall survival. Nowadays, the widespread use of semi-invasive endoscopic methods and feacal blood tests characterised by suboptimal accuracy of diagnostic results has led to the detection of cases at later stages. New molecular noninvasive tests based on the detection of CRC alterations seem to be more sensitive and specific then the current methods. Therefore, research aiming at identifying molecular markers, such as DNA, RNA and proteins, would improve survival rates and contribute to the development of personalized medicine. The identification of “ideal” diagnostic biomarkers, having high sensitivity and specificity, being safe, cheap and easy to measure, remains a challenge. The purpose of this review is to discuss recent advances in novel diagnostic biomarkers for tumor tissue, blood and stool samples in CRC patients.

show abstract

“…M2-PK, commonly upregulated in numerous cancers, plays a critical role in glucose metabolism, as well as being essential in gene transcription and tumorigenesis. [ 12 ]…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of pyruvate kinase isoenzyme type M2 in colon cancer proven with colonoscopy

et al. 2020

View full text Add to dashboard Cite

Background: Colonoscopy is the gold standard for colon cancer screening; it is also associated with a high cost and complication. Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed M2 pyruvate kinase (M2-PK). The aim of this study was to determine the diagnostic accuracy of fecal M2-PK for colon cancer. Materials and Methods: Forty-nine patients with colon cancers and 49 healthy controls were selected consecutively among individuals undergoing screening colonoscopy for various indications. The diagnosis was confirmed by histology. M2-PK measurements were done by enzyme-linked immunosorbent assay of fecal occult blood test (FOBT) and immunological FOBT (IFOBT) according to the manufacturer's instructions. Results: M2-PK > 9 (U/mL) was the best cutoff point in the detection of colon cancers. In this cutoff point, sensitivity and specificity were 87.8% and 91.8%, respectively, and accuracy was 89.8%. The sensitivity and specificity of IFOBT were 93.9% and 100%, respectively, and accuracy was 96.9%. The sensitivity and specificity of FOBT were 65.3% and 100%, respectively, and accuracy was 82.6%. Conclusion: IFOBT with high sensitivity and specificity and accuracy and low cost is the best fecal screening test. The current study suggests that fecal M2-PK can be used for high-risk colon cancer patients and negative IFOBT that refused colonoscopy as a precolonoscopy screening test.

show abstract

Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal cancer

Cited by 14 publications

References 23 publications

Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer

Blood-Based Protein Biomarker Panel for the Detection of Colorectal Cancer

Novel Diagnostic Biomarkers in Colorectal Cancer

Diagnostic value of pyruvate kinase isoenzyme type M2 in colon cancer proven with colonoscopy

Contact Info

Product

Resources

About